Home
Resources
Publications
Use of Argatroban for Extracorporeal Life Support in Patients With Nonheparin-Induced Thrombocytopenia: Analysis of 10 Consecutive Patients

Use of Argatroban for Extracorporeal Life Support in Patients With Nonheparin-Induced Thrombocytopenia: Analysis of 10 Consecutive Patients

Young Su Kim, Heemoon Lee, Ji-Hyuk Yang, Kiick Sung, Gee Young Suh, Chi Ryang Chung, Jeong Hoon Yang, Yang Hyun Cho

Medicine (Baltimore). 2018 Nov;97(47):e13235.

PMID: 30461625

Abstract:

Unfractionated heparin (UFH) is currently the standard anticoagulant used in extracorporeal life support (ECLS). However, severe thrombocytopenia occurs frequently during ECLS use and it may be difficult to determine whether this represents heparin-induced thrombocytopenia (HIT) or not. In this case, UFH cannot be continued. Because a confirmatory laboratory test requires time, argatroban is empirically used if HIT is suspected. However, many patients are not found to have HIT. In non-HIT patients, the effectiveness and safety of argatroban are unclear. Thus, we investigated whether argatroban was safe and useful in patients who were suspected of having HIT and were started on argatroban, but were ultimately found to have non-HIT.We retrospectively reviewed all patients on ECLS who received the anticoagulant argatroban as an alternative to UFH between January 2014 and July 2015. The pretest clinical score (4Ts) was calculated, and a score greater than 4 was considered an indication for argatroban. The target-activated clotting time or activated partial thromboplastin time was 1.5 times the patient's upper normal value. Of 191 patients on ECLS during the study period, 10 (5.2%) were treated with argatroban infusion.No patients were found to have antiplatelet factor 4/heparin antibodies. The average maintenance dose of argatroban was 0.1 μg/kg/min. Platelet counts increased significantly following argatroban administration (P = .02). There were no anticoagulation-related complications such as bleeding or thrombosis.Our results suggest that argatroban is a safe alternative to UFH for patients with non-HIT on ECLS. Argatroban may have a more significant platelet-preserving effect than UFH, regardless of whether HIT is present.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP141396283-A	Argatroban		141396-28-3	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: